Related Experiment Video
Updated: Jul 17, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Prostate cancer following testosterone replacement in Klinefelter syndrome
Sean A Bydder1, David J Joseph, Sydney Weinstein
1Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. Sean.Bydder@health.wa.gov.au
Abstract:
Klinefelter syndrome is a common cause of hypogonadism. Testosterone replacement therapy has beneficial effects on bone, muscle and psychosexual function. However, it may remove the relative protection from adenocarcinoma of prostate, which is otherwise rare in uncomplicated Klinefelter syndrome. We report the case of a 55-year-old man with Klinefelter syndrome who developed prostate cancer after only 7 years of androgen supplementation. Androgen deprivation therapy was complicated by the presence of testosterone implants. The patient was treated with androgen blockade followed by radiation therapy. We recommend that serum prostate specific antigen (PSA) and digital rectal examinations be carried out during, as well as before androgen replacement.
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Testosterone: Functions and Regulation
Infertility in Males
Signs of Puberty
Sex-linked Disorders
Menopause
